Dimensional Fund Advisors LP Buys 56,687 Shares of Henry Schein, Inc. $HSIC

Dimensional Fund Advisors LP grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,873,004 shares of the company’s stock after buying an additional 56,687 shares during the period. Dimensional Fund Advisors LP’s holdings in Henry Schein were worth $211,734,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Invesco Ltd. raised its holdings in Henry Schein by 4.1% in the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after buying an additional 184,763 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Henry Schein by 11.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after buying an additional 256,156 shares in the last quarter. Southpoint Capital Advisors LP raised its holdings in Henry Schein by 38.9% during the fourth quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock valued at $188,950,000 after acquiring an additional 700,000 shares during the period. Bank of Montreal Can grew its holdings in Henry Schein by 3,655.7% during the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Henry Schein by 6.9% during the 4th quarter. Morgan Stanley now owns 1,495,602 shares of the company’s stock valued at $113,038,000 after purchasing an additional 96,730 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Up 1.1%

Shares of HSIC opened at $85.47 on Friday. The stock has a 50 day moving average price of $80.98 and a 200 day moving average price of $78.04. The stock has a market capitalization of $9.74 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 1.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.34.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period last year, the firm posted $1.15 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. BMO Capital Markets assumed coverage on Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective on the stock. UBS Group reiterated a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Citigroup started coverage on Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price on the stock. Mizuho lowered their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $88.62.

Insider Activity

In other news, Director William K. Daniel acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.89% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.